Navigation Links
Regulus Demonstrates Initial Progress in microRNA Biomarkers MS Collaboration and Receives Milestone Payment from Biogen Idec
Date:11/20/2013

#160;

In August 2012, Regulus entered into a research collaboration with Biogen Idec to explore microRNAs as biomarkers for disease monitoring and response to therapy. In June 2013, Regulus and Biogen Idec amended the collaboration agreement to update the research plan and criteria for success. The collaboration is initially focused on the discovery of microRNAs as biomarkers for MS. Under the transaction, Regulus has received an upfront payment and has earned an initial milestone payment and is also eligible to receive additional milestone payments. Additionally, Biogen Idec made an investment in Regulus in the form of a promissory note that converted into shares of Regulus' common stock upon the closing of the Company's initial public offering in October 2012.

About microRNAs and microRNAs as Biomarkers

The discovery of microRNAs in humans during the last decade is one of the most exciting scientific breakthroughs in recent history. microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead regulate gene expression. More than 500 microRNAs have been identified in the human genome, and over one-third of all human genes are believed to be regulated by microRNAs. microRNA expression, or function, has been shown to be significantly altered or dysregulated in many disease states, including oncology, fibrosis and metabolic diseases. Regulus believes that microRNAs are clinically relevant therapeutic targets and may be ideally suited as biomarkers for these disease states and others, like MS. 

microRNAs have been detected in bodily fluids such as blood, and emerging data has demonstrated that microRNA signatures in blood can mimic the expression profile observed in disease tissues. Regulus has a comprehensive intellectual property estate and oligonucleotide technology know-how and believes that microRNA
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology news :

1. Study demonstrates cells can acquire new functions through transcriptional regulatory network
2. New study demonstrates the role of urban greenery in CO2 exchange
3. WALTHAM® demonstrates commitment to scientific dialogue and exchange at international human animal interaction conference
4. Published clinical trial demonstrates efficacy of Sea-Band® for migraine-related nausea
5. University of Toronto study demonstrates impact of adversity on early life development
6. UT Arlington physics team demonstrates new power generation technique
7. First-in-man study demonstrates the therapeutic effect of RNAi gene silencing in cancer treatment
8. Genetic study of house dust mites demonstrates reversible evolution
9. Rotavirus vaccine developed in India demonstrates strong efficacy
10. Fingerprint Cards (FPC) Demonstrates Fingerprint Biometric Touch Sensor for Microsoft Windows 8.1
11. Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/14/2015)... , May 14, 2015  Verificient ... identity verification and online remote proctoring, announced ... software-as-a-service (SaaS) company and creator of the ... of the two companies will benefit from ... Canvas. As a fully integrated ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/7/2015)... Fingerprint Cards (FPC) introduces ... FPC,s smallest touch fingerprint sensors to date.  ... integration on the backside of the phone, and ... to integrate touch fingerprint sensors in the OEMs, ... for module manufacturers to customize the look and ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... the aid of a straightforward experiment, researchers have provided ... how ancient organic molecules came together to form the ... online this week in JBC , demonstrated how ... length. RNA, the single-stranded precursor to DNA, normally ...
... ON A new technology that could help physicians ... and potentially fatal complication called preeclampsia has been developed ... Health Research Institute of Lawson Health Research Institute. ... have changed levels in the placenta of women who ...
... Institute of Ultrasound in Medicine (AIUM) 2009 Annual Convention ... Marquis Hotel in New York City, New York, Thursday ... numbers indicate that 2009 will prove to be better ... regarded as the AIUM,s most successful convention in history. ...
Cached Biology News:New technology aims to reduce maternal and neonatal deaths 2AIUM to Host 2009 Annual Convention in New York 2
(Date:5/21/2015)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced positive updated results from its ongoing ... treatment of unresectable glioblastoma multiforme (GBM), a deadly ... is designed to investigate the preliminary efficacy and ... progressed following prior treatment with surgery, radiation and ...
(Date:5/21/2015)... King of Prussia, PA (PRWEB) May 21, 2015 ... that Julia O’Neill has joined the firm as senior ... more than 30 years of experience in the management ... the vaccines, biologics, pharmaceutical and chemical industries. , “We’re ... enhance our longstanding capabilities in data analytics,” said Dr. ...
(Date:5/20/2015)...  Select Medical Corporation ("Select") (NYSE: SEM ... early termination of the waiting period under the ... amended, applicable to the acquisition of Concentra Inc. ... that Select has created with Welsh, Carson, Anderson & ... MJ Acquisition Corporation has signed a definitive purchase ...
(Date:5/20/2015)... May 20, 2015  Haemonetics Corporation (NYSE: HAE ... & CEO, will present at The Jefferies 2015 Global ... on June 1 st , 2015 at 8:30am Eastern ... Concannon,s presentation live via webcast at: http://wsw.com/webcast/jeff88/hae ... HAE ) is a global healthcare company dedicated ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... Good Start Genetics ,™ Inc., an innovative molecular diagnostics company ... today announced it completed the initial closing of a $14 ... existing investors OrbiMed Advisors , Safeguard Scientifics, Inc. ... Sciences . Proceeds from this financing will be used to ...
... Corporation (NASDAQ: LIFE ) will exhibit ... cancer research during the American Association of Cancer Research ... April 4, in Chicago, Illinois. In addition, several of ... "From basic discovery of biomarkers to validation of ...
... of physicists at UC Santa Barbara has seen the light, ... and low-frequency laser beams at a semiconductor, the researchers caused ... smashed back into the cores they left behind. This recollision ... the current issue of the science journal Nature . ...
Cached Biology Technology:Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 2Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 3Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 4Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 5Life Technologies Showcases Leading Technologies for Cancer Research at the AACR Annual Meeting 2012 2Life Technologies Showcases Leading Technologies for Cancer Research at the AACR Annual Meeting 2012 3Life Technologies Showcases Leading Technologies for Cancer Research at the AACR Annual Meeting 2012 4Life Technologies Showcases Leading Technologies for Cancer Research at the AACR Annual Meeting 2012 5UCSB Physicists mix 2 lasers to create light at many frequencies 2UCSB Physicists mix 2 lasers to create light at many frequencies 3
... Cell Cultures (ECACC) in conjunction with the ... of England, Bristol, UK, have produced standardised ... HER2, oestrogen and progresterone receptor assays. The ... formalin fixed, breast cancer cell lines; MDA-MD-361, ...
... When Ambion introduced the highly potent TURBO ... a new standard was set in DNA removal ... of DNase I that is much more efficient ... trace amounts of unwanted DNA. TURBO DNase binds ...
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies. ...
PP2B-Abeta (C-20)...
Biology Products: